Pharmaceutical company Eli Lilly announced promising clinical trial results for a daily pill to treat obesity and diabetes, a considerable advantage over other GLP-1-based weight-loss drugs that have ...

GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

Cinnamon has been used around the world for thousands of years, both in cooking and traditional medicine. But new research ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Researchers have identified a compound that could block certain life-threatening and hard-to-treat allergic reactions.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.

While sprinkling cinnamon on food is likely safe, concentrated supplements might pose risks, especially for people taking ...

Dr. Brian Barnett shows the inside of the dosing room at Cleveland Clinic Lutheran where participants in a study looking at ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...